Isarna Therapeutics Raises €13M in Funding

Isarna Therapeutics GmbH, a Munich, Germany-based company that develops TGF-β inhibitors to fight cancer, raised €13m (US$17.8m) in equity.

Backers included new private investor AT NewTec and current investors MIG-managed funds.

The company intends to use the funds to advance its pipeline of oligonucleotides that inhibit various isoforms of TGF-β, a key molecular pathway implicated in mechanisms used by cancer cells to evade immune system detection and to aid in tumor proliferation.
Isarna Therapeutics is led by CEO Dr. Philippe Calais.



Join the discussion